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Abstract: Using nasopharyngeal carriage as a marker of vaccine
impact, pneumococcal colonization and its relation to invasive disease
were examined in children, their parents, and older adults in the United
Kingdom following introduction of 7-valent pneumococcal conjugate
vaccine (PCV7) and prior to 13-valent pneumococcal conjugate vaccine
(PCV13).
A cross-sectional observational study was conducted, collecting
nasopharyngeal swabs from children aged 25 to 55 months who had
previously received 3 doses of PCV7, their parents, and adults aged
65 years. Pneumococcal serotyping was conducted according toPauline Waight, B s, PhD, Derrick
P, MD, and Andrew J. Pollard, FRCPCH, PhD
Pneumococcus was isolated from 47% of children, 9% of parents,
and 2.2% of older adults. For these groups, the percentage of serotypes
covered by PCV7 were 1.5%, 0.0%, and 15.4%, with a further 20.1%,
44.4%, and 7.7% coverage added by those in PCV13. In each group, the
percentage of disease due to serotypes covered by PCV7 were 1.0%,
7.4% and 5.1% with a further 65.3%, 42.1%, and 61.4% attributed to
those in PCV13.
The prevalence of carriage is the highest in children, with direct
vaccine impact exemplified by low carriage and disease prevalence of
PCV7 serotypes in vaccinated children, whereas the indirect effects of
herd protection are implied by similar observations in unvaccinated
parents and older adults.
(Medicine 94(1):e335)
Abbreviations: CI = confidence interval, IPD = invasive
pneumococcal disease, NVT = nonvaccine type, PCV7 = 7-valent
pneumococcal conjugate vaccine, PCV13 = 13-valent pneumo-
coccal conjugate vaccine, WHO = World Health Organization.
INTRODUCTION
P neumococcal disease inflicts its greatest burden on childrenand the elderly. In children, it causes invasive diseases such
as meningitis, pneumonia, and bacteremia, as well as mucosal
diseases such as otitis media and sinusitis. Worldwide it is
estimated to be responsible for 11% of all deaths in children
<5 years of age, with a significant proportion of survivors going
on to develop long-term sequelae.1,2 In adults aged 65 years,
invasive pneumococcal disease (IPD), primarily in the form of
pneumonia, is estimated to have an annual incidence in the
range of 24 to 85/100,000.3 Older adults with community-
acquired pneumonia have a mortality of 37.7%4 with a further
12% requiring long-term institutional care.5
Pneumococcus normally resides asymptomatically in the
nasopharynx, rarely causing invasive disease. Studies have
demonstrated that up to 50% of children acquire the organism
by 6 months with carriage peaking at 3 years of age.6,7 Carriage
rates throughout adulthood appear to progressively decline8,9;
however, the data are relatively limited. Demographic factors
such as crowding and smoking are believed to play a role increased rates of disease seen in institu-
carriage in children who are exposed to
ithin the family or at daycare.10,13
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Colonization with pneumococcus is an integral step to
develop IPD, with the correlation between carriage and IPD
clearly established and utilized to directly assess vaccine
impact.14–16 In addition, carriage studies may also provide
information on circulating antibiotic resistance, newly emergent
serotypes, and enable predictions on the future impact of
new vaccines.
There are nearly 100 known different serotypes of pneu-
mococcus. Prior to the introduction of pneumococcal conjugate
vaccination in the United Kingdom, 12 serotypes were respon-
sible for 79% of IPD across all ages during 2004 to 2005.17 For
children <5 years of age, approximately 70% of IPD was
attributed to the serotypes (4, 6B, 9V, 14, 18C, 19F, and
23F) covered by the 7-valent pneumococcal conjugate vaccine
(PCV7) during 2004 to 2005.18 This narrow spectrum of dis-
ease-causing serotypes may reflect differences in both invasive
disease potential and carriage frequency between serotypes.19
PCV7 was introduced into the UK immunization schedule
in 2006, accompanied by a catch-up program immunizing all
those<2 years of age. Since the introduction of PCV7, there has
been >80% reduction in IPD caused by vaccine serotypes in
children aged 2 to 4 years.20 The effect of herd protection has
also been noted with indirect benefits evident in older age
groups.21,22 At the same time, there has been vaccine serotype
replacement, with increased carriage and IPD from non-PCV7
serotypes.21,23
A 13-valent pneumococcal conjugate vaccine (PCV13),
containing the 7 serotypes found in PCV7 with the addition of a
further 6 (1, 3, 5, 6A, 7F, and 19A), was incorporated into the
UK immunization schedule, replacing PCV7 from April 2010.
PCV13 contains the serotypes responsible for causing>70% of
IPD in children<5 years of age from 2007 to 2008 in the United
Kingdom.24
The transition from PCV7 to PCV13 in the UK immuniz-
ation schedule provides a unique opportunity to examine the
population effects on pneumococcal carriage and disease. Thus,
this study aims to determine the nature of pneumococcal
carriage in children, their parents, and older adults since the
introduction of PCV7 and prior to wider coverage with PCV13.
Additionally, the incidence of IPD and the relationship of
demographic factors to carriage were also examined.
MATERIALS AND METHODS
Ethics
This study was performed in accordance with the principles
of the Declaration of Helsinki and the International Conference
on Harmonization Guidelines for Good Clinical Practice. Ethical
approval was obtained from theNational Research Ethics Service
REC Numbers: 10/H0606/48 and 10/H0606/49.
Study Participants
A cross-sectional study was conducted, assessing
pneumococcal carriage among healthy children aged 25 to
55 months, their parents, and adults aged 65 years from the
Thames Valley region in the United Kingdom between Novem-
ber 2010 and September 2011. Study objectives were to deter-
mine, in a population under surveillance for IPD, the
nasopharyngeal carriage rates of serotypes contained within
PCV13 and those not contained within PCV13.
Hamaluba et alChildren born between July 2006 and February 2009 were
recruited along with a subset of their parents. Invitations to
participate in this study were distributed via the child health
2 | www.md-journal.comcomputer department and/or through their daycare facility.
Older adults were approached via their general practitioner,
attendance at the University of the Third Age (an organization
that aims to educate retired members of the community), or their
influenza vaccination clinic.
Children who had previously received PCV13, incomplete
immunization with PCV7, or parents/legal guardians unable or
unwilling to give informed consent were excluded. In the parent
and older adult groups, those who had previously received any
pneumococcal polysaccharide conjugate vaccine or were
unwilling or unable to give informed consent were excluded.
Any potential participant, who was unwell with an acute
respiratory illness, was febrile above 388C on the day of the
visit or preceding 24 hours or had a condition, which in the
opinion of the investigator would put them at risk or compro-
mise the integrity of the study, were also excluded.
Specimen Collection and Identification of
Pneumococcal Isolates
Following assessment of eligibility and attainment of
consent, the nasopharynx of each participant was swabbed
according to the World Health Organization (WHO) guide-
lines.25 A single flexible aluminum shaft swab with rayon tip
(Medical Wire & Equipment, Wiltshire, England) was passed
through the anterior nares as far as the posterior pharynx and
rotated 1808 before removal. Swabs were cut into a tube of
skim-milk-tryptone-glucose-glycerine transport medium, main-
tained at 28C to 88C, transported to the Nuffield Department of
Clinical Medicine, University of Oxford, and cultured on blood
agar within 8 hours of collection. Up to 3 morphologically
distinct a-hemolytic colonies were selected for serotyping after
overnight incubation at 378C in 5% carbon dioxide. Pneumo-
coccal isolates were identified by colony morphology. Serotyp-
ing was initially performed using the Quellung reaction with
sera from Statens Serum Institut, Copenhagen, Denmark.
Samples thatwerenontypeable after 2 attemptsviaQuellung
reaction were then analyzed by microarray-based molecular
serotyping, detecting cps genes and genome content by
arrayCGH (aCGH). Genomic DNAwas extracted as previously
described.26 Molecular serotyping was performed on DNA
extracts using the BmG@S SP-CPS v1.4.0 microarray (St.
Georges, University of London, London, United Kingdom).
Briefly, DNA sampleswere fluorescently labelled and hybridized
to the Agilent 8 15K format microarray (Agilent Technologies,
Chershire,UnitedKingdom)according tomanufacturer’s instruc-
tions for the Agilent genomic DNA ULS labelling and Oligo
aCGH hybridization reagent kits (Agilent Technologies, Cher-
shire, United Kingdom). Data were statistically analyzed using a
Bayesian hierarchical model27 to determine serotype, or combi-
nation of serotypes, present in the sample and assign a relative
abundance to each serotype detected.
National IPD Data Collection
The numbers of IPD in each age group, for each serotype,
were extracted from the national database for England and
Wales maintained by Public Health England for the correspond-
ing period of nasopharyngeal swab collection.28 Serotyping of
IPD isolates was performed by Public Health England.
Sample Size and Statistical Analysis
Medicine  Volume 94, Number 1, January 2015A sample size of 600 children was selected to provide
estimates with tight confidence intervals (CIs) that would allow
future comparison to be made after commencement of the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Pneumococcal Carriage Following PCV7PCV13 program. Comparing serotype-specific pneumococcal
carriage rates with those from studies conducted in 1999 to
20016 and 2003, this study would have approximately 90%
power at the 5% significance level to find a difference in
prevalence of 2% compared with 0%, or of 5% compared with
10%, or of 10% compared with 17%. No prior data were
available for parents and older adults in this population and
thus such projections could not be made.
Univariate logistic regression analyses were performed on
data sets from all 3 age cohorts. Subjects with missing infor-
mation for a variable were excluded from analysis for that
variable only. CIs for proportions were calculated using the
binomial exact method. Using the assumption that carriage rates
in the study population are equivalent to those across the entire
corresponding age group of England and Wales, odds ratios
(ORs) were calculated as the odds of IPD for a particular
serotype divided by the odds of carriage for the same serotype.
A value of 0.5 was added prior to calculation of ORs to correct
for 0 values. Analyses were conducted using R version 2.13.1,
Stata version 13, and GraphPad Prism 6.
RESULTS
Following screening and informed consent, 600 subjects in
the child age group were eligible for participation. Eight
children were excluded prior to swabbing, whereas swabbing
was subsequently refused in 17 subjects. The parent group
consisted of 100 enrolled subjects who all completed the study.
For the older adult group, 606 subjects were eligible following
screening and informed consent. Six participants were excluded
prior to swabbing, whereas 1 sample was received unlabelled
and was also excluded. A total of 575 children, 100 parents, and
599 older adults were, therefore, enrolled into the study between
November 2010 and September 2011 (Table 1). There was a
significant bias toward female participants in the parent group.
Nasopharyngeal Carriage Across 3 Generations
Pneumococcal serotypes were identified by Quellung
reaction on 247, 9, and 12 swabs from children, parents, and
older adults, respectively. In the corresponding groups, micro-
Medicine  Volume 94, Number 1, January 2015array analysis allowed identification of pneumococci from
a further 22, 0, and 1 sample/s. The majority of pneumococci
(13/23) identified by microarray did not possess a cps gene and
TABLE 1. Characteristics of Pneumococcal Carriage Study
Subjects
Group n (%)
Age (median) 3.22 y
Sex
Male 292 (50)
(Not recorded in 2)
Race
White 528 (92)
Black 10 (2)
Other 37 (6)
Age (median) 36.2 y
Sex
Male 3 (3)
Age (median) 72.9 y
Sex
Male 281 (47)
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FIGURE 1. Total proportion of nasopharyngeal swabs from chil-
dren (aged 25–55 months), their parents, and older adults (aged
65 years), collected between November 2010 and September
2011, which had pneumococcus identified (A). (Bars indicate 95%
CI). These were then categorized according to whether the
serotype was covered by the PCVs PCV7 and PCV13 or was a
NVT (B). IPD isolates from across England and Wales for children,
adults, and older adults, and across the corresponding time
period, were serotyped by Public Health England and categorized
according to whether the serotype was covered by the PCVs PCV7
and PCV13 or was a NVT (C). CI¼ confidence interval, IPD¼ inva-
invasive pneumococcal disease, NVT¼nonvaccine type,
PCV13¼13-valent pneumococcal conjugate vaccine, PCV7¼7-
valent pneumococcal conjugate vaccine.
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thus were classified as nontypeable. Overall, a total of 269/575
(46.8%) (95% CI 42.6–50.1), 9/100 (9.0%) (95% CI 4.2–16.4),
and 13/599 (2.2%) (95% CI 1.2–3.7) swab cultures were
positive for pneumococcus in the children, parent, and older
adult groups, respectively (Figure 1A).
Nasopharyngeal Carriage and IPD due to
Vaccine Serotypes
Pneumococcal serotypes were categorized according to
whether they were included in PCV7 and PCV13 or were
nonvaccine serotypes (NVTs) (Figure 1B). PCV7 serotypes
accounted for 1.5%, 0.0%, and 15.4% of the total isolates in
the children, parent, and older adult groups, respectively. In the
corresponding groups, PCV13 serotypes accounted for an
additional 20.1%, 44.4%, and 7.7% of the total isolates.
During the carriage study period, a total of 98, 1892, and 727
cases of IPD occurred across England and Wales, in children,
adult, and older adult age groups, respectively.28 These IPD
isolates were categorized according to whether the serotype
Hamaluba et alwas covered by PCV7 and PCV13 or was a NVT (Figure 1C).
PCV7 serotypes accounted for 1.0%, 7.4%, and 5.1% of isolates
from children, adult, and older adult groups, respectively. In the
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FIGURE 2. The proportion of nasopharyngeal pneumococcal carriage b
55 months (A), their parents (B), and older adults (C) collected betwee
of IPD in England and Wales, identified by Public Health England,
pneumococcal disease, NT¼nontypeable, PCV7¼7-valent pneumoc
4 | www.md-journal.comsame groups, PCV13 serotypes accounted for an additional
65.3%, 42.1%, and 61.4% of the total isolates.
Serotype-Specific Nasopharyngeal Carriage
From the 269 children who had at least 1 serotype of
pneumococcus isolated, 5 (1.9%) had 2 serotypes identified
(4 of these were by microarray). In this group, a total of 35
different serotypes were identified (Figure 2A). Within the
serotypes covered by PCV7, 6B (0.7%) was the most frequently
isolated. Of the serotypes covered by PCV13, 3 (6.6%) and 19A
(9.9%) predominated. Most frequently identified NVTs were
6C (9.1%), 11A (8.8%), and 23B (8.8%). Analysis of demo-
graphic data showed a trend toward an association between
carriage and daycare attendance (OR 1.68, 95% CI 0.96–2.96,
P¼ 0.07) (Table 2).
From the 9 isolates obtained from parents, 4 distinct
serotypes were identified, with 22F (33.3%) the most frequently
found (Figure 2B). No isolates were from serotypes covered by
PCV7. Of the additional serotypes covered by PCV13, 3
Medicine  Volume 94, Number 1, January 2015(22.2%) and 19A (22.2%) were isolated. Of the colonized
parents, 5 (55.6%) had children who also had pneumococcus
isolated; however, no parent had the same serotype as their
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TABLE 2. Pneumococcal Carriage in Children and its Relation-
ship to Demographic Factors
Carriers Noncarriers
OR
(95% CI)
P
Value
Sex
Male 140 152 Reference
Female 127 154 0.90 (0.64–1.24) 0.51
Missing 2 0 —
Is there a smoker in the house?
No 221 256 Reference
Yes 40 42 1.10 (0.69–1.76) 0.68
Missing 8 8 —
Does the child have a sibling?
No 50 66 Reference
Yes 219 239 1.21 (0.8–1.82) 0.36
Missing 0 1 —
Does the child go to daycare?
No 21 38 Reference
Yes 241 258 1.69 (0.96–2.96) 0.07
Missing 7 10 —
Ethnicity
White 251 277 Reference
Not white 18 29 0.68 (0.37–1.26) 0.23
Missing 0 0
Age, y
2 78 91 Reference
3 186 204 1.06 (0.74–1.53) 0.74
4 5 11 0.53 (0.18–1.59) 0.26
Missing 0 0
Medicine  Volume 94, Number 1, January 2015child. There was no significant association between a parents
being a carrier if their child was a carrier (P¼ 0.55) (Table 3).
In the older adult participants, pneumococcus was isolated
from 13/599 (2.2%), with 12 distinct serotypes and 1 identified
as nontypeable (Figure 2C). All serotypes identified were found
on a single occasion. Serotypes 4 and 14 were the only isolates
identified that are covered by PCV7. Of the additional serotypes
covered by PCV13, only 6A was identified. Demographic data
CI¼ confidence interval, OR¼ odds ratio.analysis demonstrated a significant relationship between the
odds of carriage and contact with preschoolers (OR 4.7, 95% CI
1.51–14.6, P¼ 0.007) (Table 4).
TABLE 3. Pneumococcal Carriage in Parents and its Relation to S
Carriers Non
Does the child have carriage?
No 4
Yes 5
Missing 0
Is there a smoker in the house?
No smokers in the house 6
Smokers in the house 2
Missing 1
CI¼ confidence interval, OR¼ odds ratio.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Serotype-Specific IPD
From IPD samples across all the age groups, a total of 57
different pneumococcal serotypes were identified. For each age
group, there were 20, 47, and 43 different serotypes identified in
children, adults, and older adults, respectively. In all age groups,
the 3 serotypes with the highest proportion of IPD are included
in PCV13 but not PCV7. These were serotypes 1 (23.5%), 7F
(20.4%), and 19A (16.3%) in the child group, 19A (14.1%), 7F
(11.2%), and 3 (10.9%) in the adult group, and 7F (24.4%), 1
(17.9%), and 19A (12.0%) in the older adult group (Figure 2).
The largest discordances, between carriage and disease, were
seen with serotypes 1 and 7F for all groups. The ORs of IPD to
carriage were calculated for each of the serotypes covered by
PCV13 in the child group and related to carriage frequency
(Figure 3). These data demonstrate that both serotypes 1 (OR
21.4, 95%CI 7.2–63.7) and 7F (OR 8.8, 95%CI 3.7–20.8) have
the highest odds of IPD relative to carriage. The serotype-
specific OR relative to carriage frequency of NVTs for children
demonstrates the spread of different IPD potentials (Supple-
mentary Figure 1, http://links.lww.com/MD/A122). Similar
calculations in the parent and older adult groups are not
demonstrated due to the low carriage and disease frequencies
of vaccine serotypes observed.
DISCUSSION
This is the first study to demonstrate serotype-specific
carriage of pneumococcus within 3 generations of the same
community after introduction of PCV7 into the routine immu-
nization schedule. These data demonstrate that preschool-aged
children form the primary reservoir of pneumococcal carriage in
the community, and transmission to older age groups is facili-
tated by interaction with them. The direct impact of PCV7 on
carriage and IPD is demonstrated by the low rates observed in
vaccinated children, with indirect effects implied by the low
prevalence seen in the unvaccinated parents and older adults.
The high proportion of carriage and disease attributed to the
additional serotypes covered by PCV13 suggest that introduc-
tion of the higher valency vaccine into this population will result
in a significant decrease in IPD and carriage.
The high overall carriage rates seen in the child group are
consistent with previous studies conducted in the United King-
dom and other industrialized countries.7,29,30 Comparatively
lower carriage rates were seen in the parent, and even more
so, in the older adult groups. This finding is consistent with
Pneumococcal Carriage Following PCV7current, albeit limited literature in adults from industrialized
countries, which ranges from 5.4% to 8%,30,31 and a study in
older adults showing a 0.3% carriage prevalence.8 In addition, a
moking Status
carriers OR (95% CI) P Value
50 Reference
41 1.52 (0.38–6.05) 0.55
0
77 Reference
10 2.57 (0.45–14.49) 0.29
4 —
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TABLE 4. Demographic Factors Affecting Carriage in Older Adults
Carriers Noncarriers OR (95% CI) P Value
Sex
Male 5 276 Reference
Female 8 309 1.43 (0.46–4.42) 0.54
Missing 0 1 —
Does the subject smoke?
Not a current smoker 12 526 Reference
Current smoker 1 36 1.22 (0.15–9.63) 0.85
Missing

0 24 —
Does the subject live alone?
Lives alone 3 136 Reference
Does not live alone 10 450 1.01 (0.27–3.71) 0.99
Missing 0 0
Does the subject have contact with preschoolers?
No 5 432 Reference
Yes 8 147 4.7 (1.51–14.6) 0.007
Missing 0 7 —
Hamaluba et al Medicine  Volume 94, Number 1, January 2015recent study has demonstrated oropharyngeal sampling com-
pared with nasopharyngeal sampling to have a higher yield for
detecting pneumococcus in adults.32 Progressive acquisition of
immunity due to environmental exposure to pneumococcus may
explain the age-related decline in the rate of colonization, with
serotype-specific antibody responses having been shown to
increase with age.32 However, there appears to be discordance
between IPD, carriage rates, and antibody levels in older
adults.32,33 An explanation for this is lower functional antibody
levels in older adults, such as those observed after pneumo-
CI¼ confidence interval, OR¼ odds ratio.
There are too many missing values here for reliable inference.coccal polysaccharide vaccination.34
Serotypes covered by PCV7 appear to be carried in low
proportions across all age groups, with the caveat that the
100
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FIGURE 3. The invasive disease potential expressed as an odds
ratio with 95% CI for serotypes covered by PCV13 were calculated
and represented against the proportion of nasopharyngeal car-
riage in the preschool children age group. The size of the marker is
relative to the ranking of the serotype’s OR weighting. Serotypes
4, 5, 6A, 9V, 14, and 18C were not isolated from the nasopharynx,
whereas serotype 23F did not cause disease in any children and
hence is not represented. CI¼ confidence interval, OR¼odds
ratio, PCV13¼13-valent pneumococcal conjugate vaccine.
6 | www.md-journal.comproportions in the older adult group are difficult to interpret
given the low overall rate of carriage. Similarly, the proportion
of IPD due to serotypes covered by PCV7 is low in all age
groups and in line with the carriage rates. Carriage studies
performed in children from the United Kingdom prior to
introduction of PCV7 in 2006 demonstrated higher carriage
rates of the serotypes covered by PCV7.6,30,35,36 The study by
Hussain et al30 in 2005 demonstrated that 52% of pneumococcal
carriage isolates from children aged 3 to 4 years were covered
by PCV7 serotypes. Similarly, it was shown that 56% of
pneumococcal positive swabs from infants <6 months of age
were serotypes covered by PCV7.6 These studies are in marked
contrast to the 1.5% of samples from children in the current
study that are included in PCV7. This striking difference in
carriage of PCV7 serotypes pre- and postvaccine introduction is
in keeping with the findings (from 31.9 to 3.6%) by Flasche et
al37 in 2011.
Surveillance of IPD cases in children and adults from
England and Wales has demonstrated a discernible decline in
disease due to vaccine serotypes as PCV7 has been intro-
duced.24 By contrast, there has been an increase in IPD due
to the NVTs following PCV7 introduction.35 This is consistent
with the serotype replacement described in other settings, where
PCVs have been utilized.36 Development of herd protection,
post-PCV7 introduction into a community immunization pro-
gram, has been demonstrated in other settings by the reduction
in carriage and IPD due to the serotypes covered by the vaccine
in unvaccinated adults.22,23 It is believed that this process occurs
by reducing transmission of the serotypes covered by the
vaccine from vaccinated children who form the reservoir of
carriage within the community. Thus, the findings of reduced
carriage and IPD due to the vaccine-covered serotypes in
unvaccinated adults in this study are consistent with this
hypothesis of herd protection.
Different serotypes appear to have differing characteristics
in their ability to colonize a host and initiate disease. Prior
studies have shown serotypes 1, 5, and 7F to have a high
invasive disease potential, but these are relatively infrequently
isolated from carriers.37,38 In contrast, serotypes 6B, 19F, and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
23F have lower attack rates but are more frequently car-
ried.15,16,38 Similarly, in this study, serotypes 1 and 7F appeared
to have the greatest discordance between carriage and IPD in all
age groups. Serotype 19A was also responsible for high pro-
portions of IPD; however, it was also frequently carried in both
the preschool children and parent groups, which is in keep-
ing with its previously described intermediate attack rate.16
Serotypes 1, 7F, and 19A form part of the additional coverage
offered by PCV13 over PCV7, and thus the IPD data anticipate a
further significant reduction in disease following PCV13 intro-
duction.
A wide variety of demographic factors have been impli-
cated in increasing the risk of pneumococcal carriage, including
smoke exposure, housing density, and recent respiratory infec-
tion.9 Smoking or exposure to smokers within the household
could not clearly be shown to be a risk factor in this study, due to
the low numbers of smokers in the cohort. Notably those studies
that have shown a relation to smoke exposure and carriage are in
nonindustrialized settings,9,10 where there are high rates of
exposure to smoke from open fires and less awareness about
the health effects of cigarette smoke exposure. Settings where
there is increased mixing of young children such as daycare
centers and preschools or higher density of people living at
home have been shown to be risk factors for carriage.9,13,39
There was only a trend toward daycare attendance being a risk
for carriage in this study, although the study may be under-
powered as a result of the low proportion of children (14%) who
did not attended daycare in the cohort. The observation in this
study, that older adults are at significantly increased odds of being
a carrier if they had contact with preschool children, is consistent
with a prior study in Alaskan adults who were found to be more
likely to carry pneumococcus if they lived with a child<5 years
of age,22 and lends weight to the hypothesis that interaction with
the carriage reservoir is responsible for transmission.
Limitations of the study are the sample size, female
predominance in the parent group, serological identification
technique, and cross-sectional study design. Low rates of
carriage in the parent and older adult groups indicate that future
studies in these age ranges would benefit from larger sample
sizes. There was a significant overrepresentation of women in
the parent group; however, there was no indication of a sex
effect in either the children or older adult age groups. Identi-
fication of pneumococcal serotypes by the WHO-defined meth-
odology is less sensitive and more labor-intensive than DNA
detection-based modalities, which are now more readily avail-
able and provide a higher resolution of information. Despite
these limitations, the results of this study clearly demonstrate
the following: low carriage prevalence of vaccine serotypes in
unvaccinated adults, older adults, and vaccinated children, with
lower frequency of pneumococcal carriage in older age groups;
a significant relationship between carriage in older adults and
contact with preschool-aged children.
The strengths of this study are the large number of adults
and children from whom swabs were collected, the comparison
with IPD data collected across the same time period, and the
potential future use of these data for comparison in the post-
PCV13 era.
A further reduction in IPD cases is expected following
PCV13 introduction, as the bulk of IPD post-PCV7 in this study
population is due to the additional serotypes covered by the
higher valency vaccine. Emergence of replacement serotypes
Medicine  Volume 94, Number 1, January 2015has only had a small impact on IPD, with the prevalence of
emergent serotypes readily detectable by continued scrutiny of
the carriage reservoir.
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have recommended, on the basis of current data, that ongoing
surveillance for serotype replacement takes place.40 Carriage
studies are warranted to provide information on the character-
istics of circulating pneumococci in a population, as a surrogate
of the potential impact of vaccines, and to inform clinical
decision-making and future vaccine development.
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